Delivery Order SPE2DB22D2108-SPE2DB25FU5YU
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $8,478.28 by the Defense Logistics Agency on August 14, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. The contract utilizes firm fixed pricing and is classified as a non-set-aside, competitively awarded delivery order with an ultimate completion date of August 15, 2025. This award falls under AmerisourceBergen's existing Indefinite...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $27,370.16 on August 8, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors under a firm fixed-price contract. The award was competitively procured with no set-aside designation and is scheduled for completion by August 11, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,237.27 by the Defense Logistics Agency on August 13, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and was awarded competitively with no set-aside designation. The award demonstrates the agency's continued reliance on AmerisourceBergen as a critical...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $2,287.74 by the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. The contract is structured as a firm fixed price delivery order with an ultimate completion date of August 13, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation and represents a child...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $5,016.72 by the Defense Logistics Agency (DLA) on September 2, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. The contract is a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award represents a non-set-aside, competitively awarded transaction under the company's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency (DLA) on September 4, 2025, for Zepbound 15 mg/0.5 ml pen injections. This non-set-aside, competitively awarded contract is valued at $6,455.58 with firm fixed pricing and is scheduled for completion by September 5, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $7,509.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on August 19, 2025, with ultimate completion scheduled for August 20, 2025. This competitive award, placed under no set-aside designation, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $22,877.40 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, designated SPE2DX and valued at $999,999,999. The delivery location is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections, valued at $6,035.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- SPE2DB22D2108Indefinite Delivery Contract
- SPE2DB22D2108-SPE2DB25FU5YUDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 25, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injections. The contract carries a ceiling value of $14,492.64 and is structured as a firm fixed price delivery order with an ultimate completion date of September 26, 2025. This award was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order supports the Defense Logistics Agency's Medical Supply Chain mission, which provides pharmaceuticals and medical supplies to military healthcare systems and other federal health programs. Zepbound, a GLP-1 receptor agonist medication used in diabetes and weight management, exemplifies the range of specialty pharmaceuticals that AmerisourceBergen supplies through its federal contracts. The company's comprehensive pharmaceutical prime vendor arrangement with DLA enables it to fulfill medical supply needs for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare entities, demonstrating its critical role in supporting military medical readiness and veteran healthcare initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.5k | 9/25/25 |